Towa Pharmaceutical (4553) Q4 2025 earnings summary

Executive summary

• Consolidated net sales for FY2025/3 rose 13.9% year-over-year to ¥259.6 billion, driven by strong demand and sales growth across all segments, especially in domestic generics and improved subsidiary performance.

• Gross profit increased 16.4% year-over-year, with improved sales mix and lower cost of sales ratio, especially at Sunsho Pharmaceutical and Towa INT.

• Operating profit surged 31.7% year-over-year to ¥23.2 billion, supported by higher gross profit and a lower SGA ratio.

• Profit attributable to owners of parent increased 17.4% year-over-year to ¥18.99 billion.

• The company advanced its 6th Medium-term Business Plan, focusing on expanding production capacity, quality control, and group synergies.

Financial highlights

• Net sales: ¥259.6 billion (+13.9% YoY); Gross profit: ¥94.7 billion (+16.4% YoY); Operating profit: ¥23.2 billion (+31.7% YoY); Ordinary profit: ¥26.2 billion (+6.8% YoY); Net income: ¥18.99 billion (+17.4% YoY).

• Operating profit margin improved to 9.0% (from 7.7% YoY); ROIC rose to 6.0% (from 4.7% YoY); equity ratio improved to 36.5%.

• Total assets increased to ¥470.8 billion, with net assets at ¥171.6 billion.

• Cash and cash equivalents at year-end were ¥45.46 billion, up ¥15.8 billion year-over-year.

• R&D expenses increased to ¥13.01 billion (+17.8% YoY), with a consolidated R&D expense-to-sales ratio of 6.3%.

Outlook and guidance

• FY2026/3 consolidated net sales projected at ¥280.0 billion (+7.9% YoY), operating profit at ¥27.0 billion (+16.2% YoY), and net income at ¥17.7 billion (-6.8% YoY).

• Ordinary profit forecasted to decline 3.3% due to exclusion of derivative valuation gains amid FX uncertainty.

• Production capacity at Yamagata Plant to be expanded, supporting further sales growth.

• R&D expense-to-sales ratio guideline set at approximately 7%.

• The domestic generics industry faces ongoing challenges from price revisions, quality assurance, and supply stability, with additional uncertainty from rising costs and geopolitical risks.